Gonadorelin

GnRH

Grade C: Preliminary or limited human evidence

TL;DR: Gonadorelin (GnRH) is a synthetic decapeptide identical to the body's own gonadotropin-releasing hormone. It has a documented history of clinical use for diagnosing pituitary-gonadal axis function and treating hypogonadotropic hypogonadism via pulsatile delivery, supported by case series and observational studies. No large randomized controlled trials of compounded subcutaneous gonadorelin for hypogonadism have been published; the available human literature consists of small cohorts and case reports. No FDA-approved gonadorelin product is currently marketed in the United States; the original branded formulations (Factrel, LutrePulse) were withdrawn from the market.

Key Takeaways

Grade C: Preliminary or limited human evidence
Withdrawn: No currently marketed FDA-approved product; the prior branded products were discontinued. Available via 503A compounding (Category 1).
Compounding: Gonadorelin previously held FDA approval and the product was later withdrawn for commercial reasons; it is not an active 503A bulk-substance candidate.

Gonadorelin chemical structure — Structure via PubChem CID 638793

Mechanism

Gonadorelin binds GnRH receptors on pituitary gonadotroph cells, stimulating pulsatile release of LH and FSH, which in turn drive gonadal testosterone and sperm/egg production.

Evidence

Gonadorelin (GnRH) is a synthetic decapeptide identical to the body's own gonadotropin-releasing hormone. It has a documented history of clinical use for diagnosing pituitary-gonadal axis function and treating hypogonadotropic hypogonadism via pulsatile delivery, supported by case series and observational studies. No large randomized controlled trials of compounded subcutaneous gonadorelin for hypogonadism have been published; the available human literature consists of small cohorts and case reports. No FDA-approved gonadorelin product is currently marketed in the United States; the original branded formulations (Factrel, LutrePulse) were withdrawn from the market.

Safety and risks

Because no FDA-approved gonadorelin product is currently available, there is no active post-market safety surveillance for compounded formulations, and quality, potency, and sterility vary by pharmacy. Documented adverse effects from historical clinical use include injection-site reactions, flushing, nausea, headache, and rare hypersensitivity reactions including anaphylaxis. Rapid or non-pulsatile administration can cause paradoxical suppression of the hypothalamic-pituitary-gonadal axis rather than stimulation. Long-term data on compounded subcutaneous gonadorelin specifically are absent. Use without confirmed hypogonadotropic hypogonadism diagnosis carries the risk of inappropriate hormonal disruption.

Interactions

Concurrent use with sex steroids, androgens, or hormonal contraceptives may alter pituitary response; gonadotropin-based therapies (hCG, FSH) may have additive or competing effects.

Federal compounding status

FDA-approved drug as of 2026-06-02.

An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.

Compounding legality

Gonadorelin previously held FDA approval and the product was later withdrawn for commercial reasons; it is not an active 503A bulk-substance candidate.

Sources

Gonadorelin is Withdrawn. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 1, 2026 by PeptideGrids editorial team (independently audited).